GTPase

New Representatives & Officers Added to Association of Executive Search & Leadership Consultants' Americas, EMEA & APAC Councils

Retrieved on: 
Thursday, April 4, 2024
Olive, Financial services, Health care, Panasonic Executive Partner, Council, Russell Reynolds, Marketing, Gulf Cooperation Council, Partner, Leisure, Partnership, Business, Education, Russell Reynolds Associates, Emerging market, Organization, Communication, Associate, Heidrick & Struggles, Insurance, Consultant, Chair, Final good, Entrepreneurship, Partner (business rank), GTPase, Local government, MENA, Completeness, Region, Multimedia, Government, Management

NEW YORK, April 4, 2024 /PRNewswire-PRWeb/ -- The Association of Executive Search and Leadership Consultants (AESC), representing the top executive search and leadership consulting firms worldwide, today announces 2024 officers and representatives appointed to AESC's Americas Council, EMEA Council and APAC Council. Each Council consists of elected officers and representatives from AESC Member executive search and leadership advisory firms from across their respective region.

Key Points: 
  • NEW YORK, April 4, 2024 /PRNewswire-PRWeb/ -- The Association of Executive Search and Leadership Consultants (AESC), representing the top executive search and leadership consulting firms worldwide, today announces 2024 officers and representatives appointed to AESC's Americas Council , EMEA Council and APAC Council .
  • Each Council consists of elected officers and representatives from AESC Member executive search and leadership advisory firms from across their respective region.
  • She currently specializes in executive search and leadership consulting for senior management in the local and Latin American markets.
  • Thorsten Amend-Schnaar , Frankfurt-based Executive Partner at Höchsmann & Company GmbH & Co. KG, has provided executive search and leadership consulting since 2013.

Beacon Therapeutics Announces Positive 12-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa

Retrieved on: 
Thursday, February 8, 2024
Schepens Eye Research Institute, VISTA, GTPase, Patient, Safety, Medical genetics, RPGR, Retina, Therapy, Science, Microperimetry, Retinitis pigmentosa, Pharmaceutical industry

Response rates in study eyes treated with a low dose (7.5 E+10 vg/eye) of AGTC-501 were similar to the untreated fellow eyes in the high dose cohort (0% for both).

Key Points: 
  • Response rates in study eyes treated with a low dose (7.5 E+10 vg/eye) of AGTC-501 were similar to the untreated fellow eyes in the high dose cohort (0% for both).
  • In addition, patients in the high dose cohort also demonstrated a robust improvement in visual function, including mean retinal sensitivity.
  • XLRP is an orphan disease predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene.
  • We look forward to announcing the initiation of our Phase 2/3 VISTA trial in the first half of 2024."

Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness

Retrieved on: 
Monday, June 12, 2023
BRC, US Foods, Vance DeGeneres, University, AMD, Food, Paratriathlon, Clinical trial, Retinitis pigmentosa, CRD, Retina, GTPase, AAV, IVT, Intravitreal administration, Oxford Sciences Enterprises, Cadherin related family member 3, Nightstar, Protein, Professor, Acquisition, Patient, McLaren, Partnership, VISTA, Knowledge, Entrepreneurship, RPGR, Therapy, FDA, OSE, University of Oxford, Muscular dystrophy, Vaccine, Pharmaceutical industry, Ophthalmology, Beacon

XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene.

Key Points: 
  • XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene.
  • Beacon Therapeutics’s first pre-clinical asset is an intravitreally (IVT) delivered novel AAV based program for dry Age-related Macular Degeneration (dry AMD).
  • Beacon Therapeutics will be led by David Fellows, the former Chief Executive of Nightstar Therapeutics with over 40 years’ experience in the ophthalmology field.
  • Beacon Therapeutics is quite unique in being a company that at launch is already underpinned by excellent clinical trial data.

MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Retrieved on: 
Friday, April 21, 2023
Tissue, Abstract, ARVO, IRD, Retinitis pigmentosa, Janssen, Macular degeneration, Gene expression, Retina, GTPase, Publication, Patient, Janssen Pharmaceuticals, Annual general meeting, Association for Research in Vision and Ophthalmology, Johnson & Johnson, Research, RPGR, Pharmaceutical industry, Ophthalmology

LONDON and NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced two abstract presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting .

Key Points: 
  • LONDON and NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced two abstract presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting .
  • The second abstract will present data from MeiraGTx’s proprietary promoter platform involving the use of novel, AI-assisted engineered promoters to improve gene expression in rod photoreceptors.
  • “We are pleased to present recent data from the Phase 1/2 clinical study of our investigational gene therapy bota-vec at this year’s ARVO meeting.
  • The abstracts can be found on the ARVO Annual Meeting website .

Janssen to Highlight Innovation in Retinal Pipeline at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Retrieved on: 
Friday, April 21, 2023
Abstract (summary), ARVO, IRD, AMD, Retinitis pigmentosa, Geographic atrophy, Quality of life, Janssen, Research, Paratriathlon, GA, GTPase, Patient, Peripheral vision, Association for Research in Vision and Ophthalmology, Johnson & Johnson, RPGR, New Orleans, Janssen Pharmaceuticals, Pharmaceutical industry, Retina, Ophthalmology

RARITAN, N.J., April 21, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that five company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting in New Orleans from April 23-27, 2023. Janssen presentations will include updates from the Phase 1/2 MGT009 trial for investigational gene therapy botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) in patients with the inherited retinal disease (IRD) X-linked retinitis pigmentosa (XLRP) associated with the retinitis pigmentosa GTPase regulator (RPGR) gene, and pooled safety analysis data from two Phase 1 trials of the investigational gene therapy JNJ-81201887 (JNJ-1887); one trial in patients with geographic atrophy (GA), a late-stage and severe form of age-related macular degeneration (AMD) and one trial in wet AMD (Abstracts #5446 and #732-C0314).1,2

Key Points: 
  • Important new data on Janssen's investigational gene therapy portfolio, including botaretigene sparoparvovec (bota-vec) and JNJ-1887, will be presented
    RARITAN, N.J., April 21, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that five company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting in New Orleans from April 23-27, 2023.
  • In this new era of innovation, we're taking a cutting-edge approach to saving sight through groundbreaking technologies such as gene therapy, and we're thrilled to showcase some of this research at this year's ARVO annual meeting," said James List, M.D., Ph.D., Global Therapeutic Area Head, whose team oversees a portfolio of programs including Retina at Janssen Research & Development, LLC.
  • "We are on a bold mission to restore and preserve vision for people living with retinal diseases, and these important data bring us one step closer to building a brighter future for the patients we serve."
  • Abstracts can also be found on the ARVO Annual Meeting website.

Sarah Cannon to Present Latest Oncology Research Insights at 2022 ASCO® Annual Meeting

Retrieved on: 
Thursday, June 2, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, NUALS Arts and Literary Annual Meet, MBC, Doctor of Philosophy, Business, Sarah Cannon Research Institute, RCC, Metastatic breast cancer, Annual, Nivolumab, Research, Abstract (summary), FACP, Drug development, Melanoma, Cancer, Breast cancer, Personalized medicine, Skin cancer, HCA, Randomness, Development, GTPase, Program, Clinical, MPH, FIH, CRO, University, CDT, OVC, Jefferson Health, Society, Lung cancer, Annual general meeting, Wilms' tumor, American Society of Clinical Oncology, 2021 Essex County Council election, MS, Workforce, Safety, Clinical trial, Pharmaceutical industry, HealthONE, MD, Patient, Telehealth, Immunotherapy

Today, Sarah Cannon Research Institute announced that it will highlight its latest cancer research insights through more than 140 abstracts and presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago and online from June 3-7, 2022.

Key Points: 
  • Today, Sarah Cannon Research Institute announced that it will highlight its latest cancer research insights through more than 140 abstracts and presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago and online from June 3-7, 2022.
  • Experts from across Sarah Cannon Research Institutes network will join oncology leaders from around the globe to discuss the latest research findings that are accelerating progress in the fight against cancer.
  • Abstracts and presentations with Sarah Cannon experts as first authors will be presented by:
    Meredith McKean, MD, MPH, Director, Melanoma & Skin Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology
    Sarah Cannon Research Institute is the research arm of HCA Healthcares Cancer Institute, Sarah Cannon.
  • Sarah Cannons strategic site network includes: Hematology/Oncology Clinic, Messino Cancer Centers, Sarah Cannon Research Institute at Florida Cancer Specialists, Sarah Cannon Research Institute at HCA Midwest Health, Sarah Cannon Research Institute at HealthONE, Sarah Cannon Research Institute at Tennessee Oncology, Sarah Cannon Research Institute - United Kingdom, Sidney Kimmel Cancer Center at Jefferson Health, The Stephenson Cancer Center at the University of Oklahoma, and Zangmeister Cancer Center.

MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

Retrieved on: 
Wednesday, May 4, 2022
COVID-19, Retinitis pigmentosa, Private Securities Litigation Reform Act, GTPase, EMA, Failure, NASDAQ, GLOBE, NEW, European Medicines Agency, UCL Institute of Ophthalmology, Real-time, Retina, Safety, Research, Eye, ARVO, Janssen Pharmaceuticals, Retinal degeneration, Johnson & Johnson, RPGR, Patient, ATMP, Association, Neurodegeneration, FDA, Annual report, Gene expression, Advanced Therapy Medicinal Product, Severe cognitive impairment, Priority, RP, Loss, Public opinion, Achievement, Genetics, SEC, Technology, Ros, Xerostomia, Central nervous system, Nature, Pharmaceutical industry, Vaccine, Ophthalmology

of Genetics

Key Points: 
  • of Genetics
    Patients in the multicenter, open-label Phase 1/2 trial were given botaretigene sparoparvovec subretinally at 1 of 3 doses to the worse-seeing eye.
  • Exploration of the association between the location of botaretigene sparoparvovec delivery and changes in retinal sensitivity was undertaken by overlaying bleb topography onto sensitivity heat maps.
  • Data from the study indicates improvements in photoreceptor function assessed through 12 months post-treatment suggesting local efficacy of botaretigene sparoparvovec gene therapy in XLRP patients.
  • These data are consistent with the reported Phase 1/2 trial positive results for botaretigene sparoparvovec in patients with RPGR-associated XLRP.

Frontier Medicines Announces Oral Presentation on Dual-Acting Inhibitors of the Active and Inactive Forms of KRAS G12C at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022
AACR, American Association for Cancer Research, Protein, MIA, MAPK, Perk, Precision medicine, KRAS, GLOBE, Patient, American Association, GTP, Active, GTPase, Pancreatic cancer, Association, Proteome, CEO, SAN, Pharmaceutical industry

However, current inhibitors bind only to the inactive (GDP-bound) form of KRASG12C, and a majority of patients on treatment fail to achieve a clinical response or relapse.

Key Points: 
  • However, current inhibitors bind only to the inactive (GDP-bound) form of KRASG12C, and a majority of patients on treatment fail to achieve a clinical response or relapse.
  • Our preclinical data demonstrate that by targeting both the active (GTP-bound) and inactive (GDP-bound) states of KRASG12C, our compounds have potent cellular activity in cancer models where single-acting KRAS inhibitors do not.
  • The study was conducted in preclinical models that are both sensitive (NCI-H358 and MIA PaCa-2) and resistant (NCI-H2122) to first-generation KRASG12C inhibitors (adagrasib and sotorasib).
  • To model resistance to first-generation inhibitors, an A59G mutation was introduced into KRASG12C, abrogating GTPase activity.

Cyclica launches Perturba Therapeutics, a spin out from the University of Toronto, creating the next-generation oncology biotech

Retrieved on: 
Wednesday, February 9, 2022
Oncology, Professional Services, Health, Venture Capital, Clinical Trials, Pharmaceutical, Biotechnology, SIMPL, Large-cell lung carcinoma, Biomedical Research, EGFR, Colon, KRAS, Federica Panicucci, AI, Doctor of Philosophy, PPI, SVP, Cancer, Breast, Program, GTPase, Technology, Patient, University, Drug design, CEO, Cystic fibrosis, Health, Genetics, Lung, Entrepreneurship, Research, Center, Inc., Principal, Disease, Lists of diseases, Drug discovery, Biology, Igor Stagljar, MD, Genomics, Fine chemical, Pharmaceutical industry, Vaccine, Cyclica, Homorthodes perturba, Medicine, Perturba, Cyclica, the Stagljar Lab and the Donnelly Centre, PERTURBA, CYCLICA, THE STAGLJAR LAB AND THE DONNELLY CENTRE

Perturba is taking this challenge on by integrating Cyclicas comprehensive AI-augmented proteome-wide drug design technology with two first-in-class live cell-based assays from the Stagljar Lab.

Key Points: 
  • Perturba is taking this challenge on by integrating Cyclicas comprehensive AI-augmented proteome-wide drug design technology with two first-in-class live cell-based assays from the Stagljar Lab.
  • Perturba will initially focus on advancing two EGFR triple mutant inhibitors for non-small cell lung cancer, and four programs targeting small GTPases for various intractable cancers.
  • Naheed Kurji, Co-Founder, CEO and President of Cyclica indicates that More than half of all human disease-related proteins are considered undruggable using conventional approaches.
  • Cyclica will provide initial funding for Perturba and will seek external funding from strategic partners as required.

4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa

Retrieved on: 
Monday, January 10, 2022
Clinical trial, Retinitis pigmentosa, Safety, US, Tissue, Risk, GTPase, AMD, Man, Cystic fibrosis, Security (finance), Patient, United Kingdom, Marketing, NASDAQ, U.S. Securities and Exchange Commission, Quality of life, Fabry disease, Program, Food, Review, Retina, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nyctalopia, Therapy, Senior, Ophthalmology, Private Securities Litigation Reform Act, Fast Track, Communication, Severe cognitive impairment, Molecule, Visual acuity, COVID-19, FDA, Choroideremia, Cardiology, RPGR, GLOBE, Prevalence, Pharmaceutical industry

Food and Drug Administration(FDA) has granted Fast Track Designation for 4D-125 for treatment of patients with inherited retinal dystrophies due to defects in the RPGR gene, including X-linked Retinitis Pigmentosa (XLRP).

Key Points: 
  • Food and Drug Administration(FDA) has granted Fast Track Designation for 4D-125 for treatment of patients with inherited retinal dystrophies due to defects in the RPGR gene, including X-linked Retinitis Pigmentosa (XLRP).
  • Fast Track Designation is a landmark event for the program and underscores the potential of 4D-125 to address a significant unmet need for those living with XLRP.
  • 4D Molecular Therapeutics, 4DMT, Therapeutic Vector Evolution, and the 4DMT logo are trademarks of 4DMT.
  • 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements.